4.5 Article

Toward a better definition of focal cortical dysplasia: An iterative histopathological and genetic agreement trial

Journal

EPILEPSIA
Volume 62, Issue 6, Pages 1416-1428

Publisher

WILEY
DOI: 10.1111/epi.16899

Keywords

brain; classification; epilepsy; genes; neuropathology; seizure

Funding

  1. German Research Council [DFG Bl 421/4-1]
  2. National Institutes of Health (National Institute of Neurological Disorders and Stroke) [R01 NS097719]
  3. European Research Council [682345]
  4. program Investments of the Future [ANR-10-IAIHU-06, ANR-18-RHUS-0005]
  5. Cleveland Clinic Epilepsy Center
  6. ZonMw, Programme Translational Research [95105004]
  7. Italian Ministry of Health
  8. Manton Center for Orphan Disease Research at Boston Children's Hospital
  9. Sao Paulo Research Foundation (FAPESP) grant [2013/07559-3]
  10. Brain Tumour Charity
  11. Children with Cancer UK
  12. Great Ormond Street Hospital (GOSH) Children's Charity
  13. Olivia Hodson Cancer Fund
  14. Cancer Research UK
  15. National Institute of Health Research (NIHR)
  16. Agence Nationale de la Recherche (ANR) [ANR-18-RHUS-0005] Funding Source: Agence Nationale de la Recherche (ANR)

Ask authors/readers for more resources

This study focused on the genetic and histopathological agreement of Focal Cortical Dysplasia (FCD) diagnosis, revealing improved consistency among neuropathologists with the addition of immunostainings and the Delphi consensus method. Genetic testing results identified mutations in genes such as MTOR, AKT3, and SLC35A2 that are associated with FCD, providing insight for the diagnosis of FCD subtypes.
Objective Focal cortical dysplasia (FCD) is a major cause of difficult-to-treat epilepsy in children and young adults, and the diagnosis is currently based on microscopic review of surgical brain tissue using the International League Against Epilepsy classification scheme of 2011. We developed an iterative histopathological agreement trial with genetic testing to identify areas of diagnostic challenges in this widely used classification scheme. Methods Four web-based digital pathology trials were completed by 20 neuropathologists from 15 countries using a consecutive series of 196 surgical tissue blocks obtained from 22 epilepsy patients at a single center. Five independent genetic laboratories performed screening or validation sequencing of FCD-relevant genes in paired brain and blood samples from the same 22 epilepsy patients. Results Histopathology agreement based solely on hematoxylin and eosin stainings was low in Round 1, and gradually increased by adding a panel of immunostainings in Round 2 and the Delphi consensus method in Round 3. Interobserver agreement was good in Round 4 (kappa = .65), when the results of genetic tests were disclosed, namely, MTOR, AKT3, and SLC35A2 brain somatic mutations in five cases and germline mutations in DEPDC5 and NPRL3 in two cases. Significance The diagnoses of FCD 1 and 3 subtypes remained most challenging and were often difficult to differentiate from a normal homotypic or heterotypic cortical architecture. Immunohistochemistry was helpful, however, to confirm the diagnosis of FCD or no lesion. We observed a genotype-phenotype association for brain somatic mutations in SLC35A2 in two cases with mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy. Our results suggest that the current FCD classification should recognize a panel of immunohistochemical stainings for a better histopathological workup and definition of FCD subtypes. We also propose adding the level of genetic findings to obtain a comprehensive, reliable, and integrative genotype-phenotype diagnosis in the near future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available